Millennium Management LLC raised its position in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 242.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 858,407 shares of the biotechnology company’s stock after buying an additional 607,588 shares during the period. Millennium Management LLC owned 1.29% of Sarepta Therapeutics worth $113,464,000 as of its most recent filing with the SEC.
A number of other large investors have also recently bought and sold shares of SRPT. Clarus Wealth Advisors purchased a new stake in Sarepta Therapeutics in the 2nd quarter valued at about $124,000. Rockefeller Capital Management L.P. purchased a new stake in Sarepta Therapeutics in the 2nd quarter valued at about $162,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in Sarepta Therapeutics in the 2nd quarter valued at about $185,000. Keybank National Association OH purchased a new stake in Sarepta Therapeutics in the 2nd quarter valued at about $206,000. Finally, Kovack Advisors Inc. purchased a new stake in Sarepta Therapeutics in the 2nd quarter valued at about $217,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.
Sarepta Therapeutics stock opened at $152.76 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 9.89 and a current ratio of 10.88. Sarepta Therapeutics Inc has a twelve month low of $42.97 and a twelve month high of $176.50.
SRPT has been the subject of several analyst reports. Morgan Stanley upgraded shares of Sarepta Therapeutics from an “equal weight” rating to an “overweight” rating and set a $163.00 price objective for the company in a research note on Wednesday, August 1st. HC Wainwright set a $267.00 price target on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 9th. Citigroup began coverage on shares of Sarepta Therapeutics in a research note on Tuesday, August 14th. They set a “buy” rating for the company. Cowen restated a “buy” rating and set a $178.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, August 9th. Finally, BidaskClub lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Three analysts have rated the stock with a hold rating, twenty-two have given a buy rating and two have issued a strong buy rating to the company. Sarepta Therapeutics currently has an average rating of “Buy” and a consensus target price of $154.21.
In other Sarepta Therapeutics news, Director Richard Barry sold 75,000 shares of the business’s stock in a transaction on Wednesday, June 27th. The shares were sold at an average price of $130.34, for a total value of $9,775,500.00. Following the completion of the sale, the director now directly owns 3,170,432 shares of the company’s stock, valued at $413,234,106.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Douglas S. Ingram purchased 16,000 shares of the stock in a transaction on Wednesday, August 15th. The stock was acquired at an average cost of $125.26 per share, with a total value of $2,004,160.00. Following the completion of the purchase, the chief executive officer now directly owns 399,250 shares of the company’s stock, valued at $50,010,055. The disclosure for this purchase can be found here. Insiders sold 158,782 shares of company stock valued at $21,237,444 over the last three months. 7.90% of the stock is currently owned by insiders.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Further Reading: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.